Clinical Trial Update: Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating VIA-2291 for reducing inflammatory activity in atherosclerotic vascular disease in patients undergoing elective carotid endarterectomy;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• VIA-2291

Snippet

Sponsor: Tallikut Pharmaceuticals, Inc. | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2012-07-20